---
title: "Definium Therapeutics Sets $805 Million Public Offering at $34; Underwriting Agreement Signed"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290742592.md"
description: "Definium Therapeutics signed an underwriting agreement to sell over 20.5 million common shares at $34 each, raising approximately $805 million in gross proceeds. Net proceeds are estimated at $758 million after fees. The capital will fund R&D and commercialization preparations for DT120 ODT, alongside general corporate purposes. The offering closes on June 25, 2026, with J.P. Morgan and other firms acting as underwriters."
datetime: "2026-06-24T21:23:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290742592.md)
  - [en](https://longbridge.com/en/news/290742592.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290742592.md)
generator: "portal-rs"
---

# Definium Therapeutics Sets $805 Million Public Offering at $34; Underwriting Agreement Signed

Definium Therapeutics entered into an underwriting agreement to sell 20,588,236 common shares at $34.00 per share, with underwriters exercising in full a 3,088,235-share option, for expected gross proceeds of about $805 million. Net proceeds are estimated at approximately $758 million after fees and expenses. The funds will support R&D, potential commercialization preparations for DT120 ODT if approved, and general corporate purposes. Closing is expected on June 25, 2026.

**Agreement details:**

-   **Agreement type**: Underwriting agreement for common stock offering
-   **Counterparty**: J.P. Morgan Securities; Jefferies; Leerink Partners; BofA Securities, as representatives of the underwriters
-   **Signed / Effective**: Jun 23 2026 / same
-   **Duration / Termination**: At will
-   **Reason**: Raise capital for R&D and commercialization prep

Original SEC Filing: Definium Therapeutics, Inc. \[ DFTX \] - 8-K - Jun. 24, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Definium Therapeutics to Participate at Upcoming Investor Conferences and Events | DFTX Stock News](https://longbridge.com/en/news/297036608.md)
- [What Do Definium Therapeutics (DFTX) Phase 3 GAD Results Mean For DT120?](https://longbridge.com/en/news/295821556.md)
- [DEFI: Record FY2025 results and global expansion highlight strong growth and deep undervaluation](https://longbridge.com/en/news/298042208.md)
- [Defence Therapeutics completes $9.6 million private placement at $0.55 per unit](https://longbridge.com/en/news/298138132.md)
- [Shenyu: Knowledge and Practice in the AI Era](https://longbridge.com/en/news/298032664.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**